LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VERU
Veru Inc.
There isn't enough reported data to score VERU yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VERU Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
VERU's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VERU PE Valuation
VERU has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VERU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect VERU's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VERU on earnings quality, reporting a profit while its opponent remains loss making.
VERU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.58 | +$1.65 |
| Q1 2026 | -$0.78 | +$1.65 |
| Q4 2025 | -$1.16 | +$1.47 |
| Q3 2025 | -$1.50 | +$1.33 |
| Q2 2025 | -$2.23 | +$0.57 |
| Q1 2025 | -$2.43 | +$0.47 |
| Q4 2024 | -$2.63 | +$4.37 |
| Q3 2024 | -$2.83 | +$7.97 |
VERU is still losing money, but far less than before: $0.58 per share over the past year, against $17.30 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 100% for VERU.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
VERU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $6.7M | +72% |
| Q2 2024 | $4M | +18% |
| Q1 2024 | $4.1M | -37% |
| Q4 2023 | $2.1M | -15% |
| Q3 2023 | $3.9M | +49% |
| Q2 2023 | $3.3M | -65% |
| Q1 2023 | $6.6M | -49% |
| Q4 2022 | $2.5M | -82% |
VERU's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -123% | +88 points |
| Q2 2024 | -277% | -41 points |
| Q1 2024 | -239% | +359 points |
| Q4 2023 | -368% | +1051 points |
| Q3 2023 | -212% | +1514 points |
| Q2 2023 | -236% | -8.4 points |
| Q1 2023 | -599% | -508 points |
| Q4 2022 | -1419% | -1384 points |
VERU's operating margin was −123% last quarter, up 88 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VERU on cash generation, producing positive trailing cash flow while its opponent burns cash.
VERU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.5M | +$15.1K |
| Q1 2026 | -$8.9M | -$1.2M |
| Q4 2025 | -$6.2M | +$5.2M |
| Q3 2025 | -$5.5M | -$1.1M |
| Q2 2025 | -$5.5M | +$218.1K |
| Q3 2024 | -$4.4M | +$5.3M |
| Q2 2024 | -$5.7M | +$12.8M |
| Q3 2023 | -$9.7M | +$11.3M |
VERU has burned cash in almost every quarter: −$26M over the past year, against −$29M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VERU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VERU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +57% | +8.4M shares |
| 3 years | +161% | +14.2M shares |
| 5 years | +189% | +15.1M shares |
| Available history | +264% | +16.7M shares |
VERU has 23M diluted shares, up 57% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VERU Net Leverage
VERU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VERU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 9.7 | Oversold |
VERU's weekly RSI is 39 (neutral) and its Stochastic is 10 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VERU PE vs Healthcare Sector
VERU has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VERU on trend strength, trading above more of its moving averages.
VERU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.31 | 8.2% below |
| 20 week MA | $2.45 | 13% below |
| 50 week MA | $2.47 | 14% below |
| 100 week MA | $3.78 | 44% below |
| 200 week MA | $7.98 | 73% below |
VERU is in a downtrend: it's below all five of its weekly moving averages, and 73% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VERU on returns for 2026, with the stronger performance.
VERU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.3 | $86.7 | +186% |
| 2021 | $86.7 | $62.9 | -27% |
| 2022 | $62.9 | $50.5 | -20% |
| 2023 | $50.5 | $7.20 | -86% |
| 2024 | $7.20 | $6.76 | -6.1% |
| 2025 | $6.76 | $2.40 | -64% |
| 2026 YTD | $2.40 | $2.12 | -12% |
VERU has finished five years in a row lower, and it's down 12% so far in 2026.